Key facts
- EnsiliTech’s last known valuation is $4.0M (Dec 2022).
- It has raised $7.5M.
- Notable investors include Innovate UK, Empirical Ventures, U.K. Department of Health & Social Care, Angel Investors Bristol, Calculus Capital — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for EnsiliTech
- ·The full record, as it builds
Funding rounds
No funding rounds for EnsiliTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EnsiliTech
Developer of a healthcare technology platform designed to prevent vaccine spoilage and degradation during storage and transport. The company's platform offers silica-based encapsulation that forms protective nanoshells around biopharmaceutical components to reduce environmental damage and aggregation, enabling vaccine manufacturers and global health organizations to extend shelf stability, reduce wastage, and support broader access.
- Sector
- Healthcare
- HQ
- Bristol, United Kingdom
- Founded
- 2021
- Employees
- 14
- Website
- ensilitech.com/
- Ownership
- Privately Held (backing)
EnsiliTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EnsiliTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EnsiliTech in its N-PORT filings yet. We sweep new filings monthly.